Short answer
Alector, Inc. (ALEC) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). GSK termination follows failed Phase 3 latozinemab and discontinued Phase 2 nivisnebart programs.
Alector, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- GSK termination follows failed Phase 3 latozinemab and discontinued Phase 2 nivisnebart programs
- Collaboration ends January 2, 2027, removing GSK partnership support for both progranulin-antibody programs
- Alector repaid $10,428,827.77 principal under its Hercules loan
- Debt repayment included accrued interest, end-of-term charges, and prepayment charges
- Loan Agreement terminated July 8, 2026, eliminating the disclosed financing obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alector, Inc. 8-K filings
Get the next ALEC 8-K as it lands
Follow ALEC for push alerts, or ask the research agent what this filing means.